Blueprint Medicines Corp. (NASDAQ:BPMC) shares saw strong trading volume on Wednesday . 543,594 shares changed hands during trading, an increase of 175% from the previous session’s volume of 197,354 shares.The stock last traded at $21.78 and had previously closed at $20.89.

A number of equities research analysts have recently commented on the company. TheStreet upgraded Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a research report on Friday, July 29th. Raymond James Financial Inc. assumed coverage on Blueprint Medicines Corp. in a report on Friday, May 27th. They issued an “outperform” rating and a $23.00 price objective on the stock. Cowen and Company reiterated a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, May 10th. Finally, Zacks Investment Research cut Blueprint Medicines Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $28.50.

The firm has a 50-day moving average price of $20.26 and a 200-day moving average price of $18.14. The firm’s market cap is $591.13 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last announced its earnings results on Tuesday, May 10th. The company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.13. The business earned $6.90 million during the quarter, compared to analysts’ expectations of $3.24 million. The firm’s revenue for the quarter was up 961.5% compared to the same quarter last year. On average, equities research analysts predict that Blueprint Medicines Corp. will post ($3.10) earnings per share for the current fiscal year.

In other news, CEO Jeffrey W. Albers sold 17,000 shares of the company’s stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $20.03, for a total value of $340,510.00. Following the completion of the sale, the chief executive officer now directly owns 92,486 shares of the company’s stock, valued at $1,852,494.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

A hedge fund recently raised its stake in Blueprint Medicines Corp. stock. RS Investment Management Co. LLC raised its position in shares of Blueprint Medicines Corp. (NASDAQ:BPMC) by 17.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 740,310 shares of the company’s stock after buying an additional 109,878 shares during the period. RS Investment Management Co. LLC owned approximately 2.73% of Blueprint Medicines Corp. worth $19,500,000 as of its most recent SEC filing.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.